Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

Stock Information for Vaxart Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vaxart Inc.

Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
Vaxart to Participate in BTIG Biotechnology Conference 2026
Vaxart Announces Results of Annual Meeting of Stockholders
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.